Fujihara, K, from Fukushima Medical University School of Medicine, participated in many clinical trials of NMOSD (12, 13, 23) and was involved in the development of guidelines for demyelinating diseases of the central nervous system, including NMOSD, MS, and myelin oligodendrocyte glycoprotein antibody-associated disease (9, 24, 25). This evidence concerns the gene MOG and demyelinating disease.